SOLIGENIX, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
SOLIGENIX, INC. (SNGX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 2.10% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-30.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2020-03-30
- SOLIGENIX, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2019 was 2.10%, a 133.33% increase from fiscal 2018.
- SOLIGENIX, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2018 was 0.90%, a 84.21% decline from fiscal 2017.
- SOLIGENIX, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2017 was 5.70%, a 44.66% decline from fiscal 2016.
- SOLIGENIX, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2016 was 10.30%, a 31.33% decline from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2019-12-31 | 2.10% 10-K · filed 2020-03-30 |
| 2018-12-31 | 0.90% 10-K · filed 2020-03-30 |
| 2017-12-31 | 5.70% 10-K · filed 2019-03-26 |
| 2016-12-31 | 10.30% 10-K · filed 2017-03-27 |
| 2015-12-31 | 15.00% 10-K · filed 2017-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |